Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 11/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 3/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10135613 | 0.94 | MCHR1 (0.51) | MCHR1CCR3LTA4H | |
| SCHEMBL10135593 | 0.94 | MCHR1 (0.51) | MCHR1CCR3LTA4H | |
| SCHEMBL4117894 | 0.86 | MCHR1 (0.65) | MCHR1SIGMAR1DRD4 | |
| SCHEMBL648348 | 0.84 | SIGMAR1 (0.60) | SIGMAR1PARP1PARP2 | |
| SCHEMBL17980959 | 0.83 | AKT1 (0.44) | MCHR1SIGMAR1DRD4CCR3PARP1 | |
| SCHEMBL17981321 | 0.82 | NSD2 (0.46) | MCHR1SIGMAR1CCR3PARP1PARP2 | |
| SCHEMBL4845655 | 0.81 | MCHR1 (0.66) | MCHR1SIGMAR1CCR3 | |
| SCHEMBL4843475 | 0.81 | MCHR1 (0.66) | MCHR1SIGMAR1CCR3 | |
| SCHEMBL10135592 | 0.80 | GPR119 (0.50) | LTA4H | |
| SCHEMBL15033052 | 0.80 | SIGMAR1 (0.60) | SIGMAR1DRD4PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT1A1, SULT1E1, SULT2A1 | MCHR1 2152/4885SIGMAR1 12/4885DRD4 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.